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The impact of systemic inflammation in nigral dopaminergic cell loss remains unclear.
Here, we have investigated the role of peripheral inflammation induced by systemic
lipopolysaccharide (LPS) administration in the MPTP-based model of Parkinson’s
disease. Brain inflammation, microglia and astroglia activation, disruption of the blood–
brain barrier (BBB) and integrity of the nigrostriatal dopaminergic system were evaluated
in response to i.p. injection of LPS, MPTP or the combination of both. Our results
showed that combinative treatment exacerbates microglia activation and enhances (i)
the appearance of galectin-3-positive microglia, recently identified as microglial disease-
associated phenotypic marker, (ii) the up-regulation of pro-inflammatory cytokines, (iii)
the occurrence of A1 neurotoxic astrocytes, (iv) the breakdown of the BBB, and (v)
the loss of dopaminergic neurons in the substantia nigra. Microglia activation was
triggered earlier than other degenerative events, suggesting that over-activation of
microglia (including different polarization states) may induce dopaminergic neuron loss
by itself, initiating the endless cycle of inflammation/degeneration. Our study revitalizes
the importance of peripheral inflammation as a potential risk factor for Parkinson’s
disease and raises the possibility of using new anti-inflammatory therapies to improve
the course of neurodegenerative diseases, including those directly aimed at modulating
the deleterious activity of disease-associated microglia.
Keywords: Parkinson’s disease, peripheral inflammation, microglia, lipopolysaccharide, neuroinflammation,
MPTP, galectin-3, dopaminergic neurons
INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s
disease (AD), which is characterized by a permanent and selective loss of dopaminergic neurons in
the substantia nigra (SN) pars compacta (Obeso et al., 2000), with the subsequent loss of dopamine
(DA) in the striatum. This loss of DA accounts for many of the symptoms that accompany the
disease, including motor dysfunction, mood alterations and cognitive impairment (Olanow et al.,
2003). Mitochondrial dysfunction, oxidative stress, excitotoxicity, alterations in the ubiquitin-
proteasome system and neuroinflammatory mechanisms have been shown to cooperate in the
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progressive death of the dopaminergic neurons (Dexter
and Jenner, 2013). In this regard, clinical and experimental
evidence suggests that PD is associated with neuroinflammatory
processes such as microglia activation, T-leukocyte infiltration,
and blood–brain barrier (BBB) dysfunction (McGeer and
McGeer, 2004; Hirsch and Hunot, 2009; Tiwari and Pal, 2017).
Microglia-associated inflammation occurs in different animal
models of PD, including those using 1-methyl-4-phenyl-
1,2,3,6 tetrahydropyridine (MPTP), 6-hydroxydopamine,
lipopolysaccharide (LPS) or rotenone (Castano et al., 1998;
Liberatore et al., 1999; Betarbet et al., 2000; Cicchetti et al., 2002;
Barnum and Tansey, 2010). More importantly, epidemiological
studies have demonstrated that regular users of non-steroidal
anti-inflammatory drugs or cyclo-oxygenase inhibitors have
about 50% lower PD and AD risk than non-users (Chen et al.,
2003, 2005; Esposito et al., 2007; Subramaniam and Federoff,
2017).
Despite the existence of several theories that attempt to explain
how nigral dopaminergic neurons die in PD, the etiology of
the disease and its possible cure, is far from been understood.
Consequently, identification of new PD risk factors is mandatory.
In the same vein, a deleterious role for peripheral inflammation
in different neurodegenerative diseases is becoming evident
(Herrera et al., 2015). For instance, aged persons exposed to
systemic infections have a twofold increased risk of AD (Tilvis
et al., 2004). Furthermore, induction of a systemic inflammatory
response led to reactivation in animal models of multiple sclerosis
(Serres et al., 2009). Moreover, Cunningham et al. (2005) showed
that systemic inflammation sensitizes microglia to switch to
an over-activated pro-inflammatory state in a model of prion
disease.
The aim of the present work was to demonstrate whether
peripheral inflammation increases neuroinflammation and
subsequent neuronal death in the MPTP-based model of
PD. Systemic inflammation was firstly induced by a single
intraperitoneal injection of LPS. We show for the first time
that LPS-induced peripheral inflammation and MPTP act
synergistically to enhance (a) the appearance of galectin-
3 expressing microglia, recently identified as a phenotypic
marker of disease-associated microglia (Keren-Shaul et al.,
2017; Krasemann et al., 2017; Mathys et al., 2017), (b) central
inflammatory response, and (c) the disruption of the BBB.
In addition, systemic inflammation increases vulnerability of
dopaminergic neurons to MTP-induced neurodegeneration
in vivo.
MATERIALS AND METHODS
Animals and Treatments
Male C57BL/6 mice (20–25 g) were used for these studies.
They were housed in groups of 4–6, at constant room
temperature of 22 ± 1◦C and relative humidity (60%),
with a 12-h light-dark cycle and free access to food and
water. Experiments were carried out in accordance with the
Guidelines of the European Union Directive (2010/63/EU)
and Spanish regulations (BOE 34/11370-421, 2013) for
the use of laboratory animals; the study was approved
by the Scientific Committee of the University of Seville.
Experiments using MPTP were carried out following the
operating instructions about the use, handling and storage of
chemical agents of the Prevention Service of the University of
Seville (SEPRUS1).
Acute MPTP models have been associated to strong
inflammatory response in the nigro-striatal dopaminergic system
(Kavanagh et al., 2015). Main MPTP acute treatment paradigm
is based on four consecutive MPTP injections (16 mg/kg
every 2 h). However, the combination of LPS and this
acute MPTP paradigm abruptly increased early death rate.
To solve this issue, we took advantage of a single injection
of MPTP at higher dose (40 mg/kg), which has been shown
to cause a selective death of nigral dopaminergic neurons
(Mejías et al., 2006). Using this MPTP paradigm, Lopez-
Barneo and colleagues demonstrated a 65% decrease of
striatal dopaminergic terminals, a 48% loss of nigral TH-
positive neurons and a 24% loss of Nissl-stained cells in
the SN evaluated 1 week after neurotoxin injection (Mejías
et al., 2006). These findings demonstrate neurodegenerative
events of the nigro-striatal dopaminergic system and make
this MPTP paradigm suitable to test whether or not the
presence of peripheral inflammation affects nigral dopaminergic
vulnerability.
Crews and colleagues demonstrated that a single dose of
5 mg/kg (i.p.) causes neuroinflammation and delayed death
of nigral dopaminergic neurons (starting 7 months after LPS
injection) (Qin et al., 2007). Besides, it is well-documented
that very little peripheral LPS enters to the brain due to
the poor passage through the BBB (Nadeau and Rivest,
1999), Consequently, to full validate the solely contribution of
peripheral inflammation in MPTP-induced neurotoxicity, we
used a LPS dose 2.5-fold lower than that used by Qin et al.
(2007). Consequently, animals were distributed within groups
according to treatments, time points and method of analysis:
The V (vehicle, control) group receiving a single i.p. injection
of both vehicles; the MPTP group, receiving a single i.p. dose
of MPTP (40 mg/kg in 0.9% sterile saline; Sigma-Aldrich, St.
Louis, MO, United States, Catalogue # M0896); the LPS group
receiving a single i.p. LPS injection (2 mg/kg in 0.9% sterile
saline; Sigma-Aldrich, St. Louis, MO, United States, Catalogue
# L4391), and the LPS/MPTP group receiving a single i.p. dose
of MPTP and LPS. In the case of using both treatments, LPS
was administered 120 min before the MPTP administration. All
treatments were administrated in a volume of 100 µl per 25 g
of body weight. At least three animals per group were used
(Table 1).
Animals were sacrificed at different time points depending
on the technique assayed. For immunohistochemistry
analysis, animals were sacrificed at 12 h, 24 h, and 2 weeks.
For qPCR assays, animals were sacrificed at 12 h. For
HPLC and stereological analysis, animals were sacrificed at
2 weeks.
1https://recursoshumanos.us.es/index.php?page=seprus
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TABLE 1 | Number of cases used for each group and each technique.
Number of animals
Striatum Substantia Nigra
Technique Control LPS MPTP LPS + MPTP Control LPS MPTP LPS + MPTP
IHC: Iba1 3 4 4/3 3 4 4/3 6/3/3 5/4/3
IF: Iba1+/Gal3+ 4 4 4 3 3 3 4 3
qPCR 5 5 5/4/3 5/4/3 5 5/4 5/4/3 6/4/3
IHC: IgG 3 3 4 3 3 3 3 3
TH counting – – – – 3 3 5 5
HPLC 4 4 3 3 – – – –
Immunohistological Evaluation: Tyrosine
Hydroxylase (TH), Glial Fibrillary Acidic
Protein (GFAP) and Iba-1
At required day and hour after the treatment, animals dedicated
to the immunohistochemistry were anesthetized with ketamine
(50 mg/kg, Ketamidor R©, Richter Pharma, Wels, Austria) and
medetomidine (10 mg/kg, Domtor R©, Ecuphar, Oostkamp,
Belgium) and perfused through the heart with 0.9% saline
followed by 40 ml of 4% paraformaldehyde in phosphate buffer,
pH 7.4. Brains were removed and then cryoprotected serially in
sucrose in PBS, pH 7.4, first in 10% (24 h), then in 20% sucrose
(24 h), and then in 30% sucrose until sunk (2–5 days). The brains
were then frozen in isopentane at −40◦C (10 min) and kept at
−40◦C. We analyzed early (12 and 24 h) and delayed response
(2 weeks) after challenge.
Thaw-mounted 25-µm coronal sections were cut on a
cryostat at−15◦C and mounted in gelatin-coated slides. Primary
antibodies used were rabbit-derived anti-tyrosine hydroxylase
(anti-TH, Sigma, 1:300), mouse-derived anti-glial fibrillary acidic
protein (anti-GFAP; Sigma, 1:400) and rabbit-derived anti-
Iba-1 (Wako, 1:500). Incubations and washes for all the
antibodies were in Tris-buffered saline (TBS), pH 7.4. All work
was done at room temperature. Sections were washed and
then treated with 0.3% hydrogen peroxide in methanol for
20 min, washed again, and incubated in a solution containing
TBS and 1% goat serum (Vector) for 60 min in a humid
chamber. Slides were drained and further incubated with
the primary antibody (Table 2) in TBS containing 1% goat
serum and 0.25% Triton-X-100 for 24 h. Sections were then
incubated for 2 h with biotinylated goat anti-rabbit IgG (Vector,
1:200). The secondary antibody was diluted in TBS containing
0.25% Triton-X-100, and its addition was preceded by three
10-min rinses in TBS. Sections were then incubated with
ExtrAvidin R©-Peroxidase solution (Sigma, 1:100). The peroxidase
was visualized with a standard diaminobenzidine/hydrogen
peroxide reaction for 6 min (do not ingest and breathe
dust).
Immunohistological Evaluation of BBB
Disruption
Breakdown of the BBB was assessed by employing a one-step
immunohistochemical detection of IgG with some modifications
TABLE 2 | Antibodies for immunofluorescence, immunohistochemistry and
Western Blot.
Antibody Catalog number
Rabbit-derived anti-TH T8700 SIGMA
Mouse-derived anti-GFAP G3893-100UL SIGMA
Rabbit-derived anti-Iba1 019-19741 Wako
Goat-derived anti-mouse biotinylated BA 9200 Vector
Goat-derived anti-occludin SC-8145 Santa Cruz
Biotechnology Inc.
Rat-derived anti-C3 SC-58926 Santa Cruz
Biotechnology Inc.
Sheep-derived anti-TH NB300-110 NOVUS
Rabbit-derived anti-Caspase 3 9662S Cell signaling
Goat-derived anti-Galectin 3 AF-1197 R&D Systems
Alexa Fluor 647 anti-mouse A31571 Invitrogen
Alexa Fluor 488 anti-rat A21208 Invitrogen
Alexa Fluor 488 anti-goat A11055 Invitrogen
Alexa Fluor 546 anti-rabbit A10040 Invitrogen
Alexa Fluor 488 anti-rabbit A21206 Invitrogen
Alexa Fluor 647 anti-sheep A-21448 Invitrogen
Goat-derived anti-rabbit biotinylated BA 1000 Vector
Goat-derived anti-mouse biotinylated BA 9500 Vector
(Tomas-Camardiel et al., 2004). Briefly, sections were incubated
for 2 h in biotinylated horse anti-mouse IgG (Vector; 1:200;
Table 2) in TBS containing 1% bovine serum albumin (BSA) and
0.2% (Triton-X-100). Visualization of IgG immunoreactivity was
identical to that described above for immunohistochemistry.
Immunofluorescence
Animals were perfused and sections were prepared as described
above. Incubations and washes for all the antibodies were
in PBS, pH 7.4. All work was done at room temperature,
unless otherwise noted. Sections were blocked with PBS
containing 5% BSA for 2 h. The slides were then incubated
overnight at 4◦C with the primary antibody (Table 2): goat-
derived anti-occludin (Santa Cruz Biotechnology Inc.; 1:50),
mouse-derived anti-GFAP (Sigma; 1:400), rat-derived anti-C3
(Santa Cruz Biotechnology Inc.; 1:50), sheep-derived anti-TH
[NOVUS (Biomol); 1:1000], rabbit-derived anti-caspase 3 (Cell
Signaling; 1:250), rabbit-derived anti-Iba1 (Wako; 1:1000) and
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goat-derived anti-galectin-3 (R&D Systems; 1:250). Primary
antibodies were diluted in PBS containing 1% BSA and
1% Triton X-100. After three washes in PBS, sections were
incubated with (Table 2) secondary antibodies conjugated
to fluorescein (Vector; 1:300), Alexa Fluor R© 488 and Alexa
Fluor R© 647 (Invitrogen; 1:200) for 2 h at room temperature
in the dark. Fluorescence images were acquired using a
confocal laser scanning microscope (Zeiss LSM 7 DUO)
and processed using the associated software package (ZEN,
2010).
Immunohistochemistry Data Analysis
For GFAP immunoreactivity, the AnalySIS imaging software
(Soft Imaging System GmbH, Münster, Germany) coupled to a
Polaroid DMC camera (Polaroid, Cambridge, MA, United States)
attached to a Leika light microscope (Leica Mikroskopie, Wetzlar,
Germany) was used. Quantification of Iba-1 and TH positive cells
in the SN was estimated according to a modified stereological
approach. In each animal, every seventh section was used with
random starting points and systematically distributed through
the anteroposterior axis of the analyzed region. For counting
cells showing Iba-1 immunoreactivity, a systematic sampling of
the area occupied by the Iba-1 positive cells in each section
was made from a random starting point with a grid adjusted
to count five fields per section. An unbiased counting frame of
known area (40 µm× 25 µm = 1000 µm2) was superimposed on
the tissue section image under a 100× oil immersion objective.
The different types of Iba-1-positive cells (displaying different
shapes depending on their activation state) were counted as a
whole and expressed as cells per mm2. The number of TH-
positive neurons in the SN was estimated using a fractionator
sampling design (Gundersen et al., 1988). Counts were made at
regular predetermined intervals (x = 150 µm and y = 200 µm)
within each section. An unbiased counting frame of known
area (15686,7 µm2) was superimposed on the tissue section
image under a 40× objective. Therefore, the area sampling
fraction was 15686,7 µm2/63380,6 µm2 = 0.248. In all animals,
25-µm sections, each 175 µm apart, were analyzed; thus, the
fraction of sections sampled was 25/175 = 0.143. The total
number of neurons in the SN was estimated by multiplying the
number of neurons counted within the sample regions by the
reciprocals of the area sampling fraction and the fraction of
section sampled.
Relative amount of IgG extravasation was measured using
Image-J software (downloaded as a free software package from
the public domain2). Areas of IgG occupancy were counted
using three randomly distributed fields per section and three
sections per animal. The system allows defining a threshold to
discern between IgG immunoreactivity and background and the
percentage of IgG occupancy measured.
Iba-1/galectin-3 co-localizing cells were counted with Image-
J software using the plugin cell counter. At least three animals
were used for each condition and number of Iba-1/galectin-
3 cells were measure in a minimum of three eyespot images
2http://rsb.info.nih.gov/ij/download.html
acquired using a confocal laser scanning microscope (Zeiss LSM
7 DUO).
Measurement of DA by
High-Performance Liquid
Chromatography (HPLC)
Analysis of striatal dopamine was performed by HPLC with
electrochemical detection. A Merck L-6200A intelligent pump
was used in conjunction with a glassy carbon electrode set
at −550 mV (DECADE II, ANTEC, Netherlands). A Merck
Lichrocart cartridge (125 mm × 4 mm) column filled with
Lichrospher reverse-phase C18 5 µm material was used. The
mobile phase consisted of a mixture of 0.05 M of sodium
acetate, 0.4 mM of 1-octanesulfonic acid, 0.3 mM of Na2EDTA
and 70 ml methanol/l, adjusted to pH 4.1 with acetic acid.
All reactive agents and water were of HPLC grade. The flow
rate was 1.0 ml/min. Measurement of DA in fresh tissue
was performed according to the method previously described
(Ismaiel et al., 2016). Concentrations of striatal DA samples
were calculated with the aid of the eDAQ PowerChrom 280
software.
Real Time RT-PCR
The results on microglial activation in terms of Iba-1
immunoreactivity showed that the highest activation takes
places after 12 h of treatment. Therefore, animals designated
to RT-PCR were perfused with saline sacrificed by decapitation
12 h after the treatment. Brains were then removed and striatum
and SN were dissected, snap frozen in liquid nitrogen and
stored at −80◦C. Real Time RT-PCR was performed essentially
as described previously (Sanchez-Hidalgo et al., 2016). Total
RNA was extracted from the SN using RNeasy R© Mini kit
(Qiagen). cDNA was synthesized from 1 µg of total RNA
using RevertAid First Strand cDNA Synthesis Kit (Thermo
Fisher Scientific) in 10 µl reaction volume as described by the
manufacturer. Real-time PCR was performed with SensiFASTTM
SYBR No-ROX Kit (Bioline), 0.4 µM primers and 4.2 µl cDNA.
Controls were carried out without cDNA. Amplification was
run in a LightCycler 480 (Roche Molecular Systems) thermal
cycler at 95◦C for 2 min followed by 40 cycles of 95◦C for
5 s and 60◦C for 15 s. Following amplification, a melting
curve analysis was performed by heating the reactions from
65 to 95◦C in 0.1◦C/s while monitoring fluorescence. Analysis
confirmed a single PCR product at the melting temperature.
β-actin served as reference gene and was used for samples
normalization. Primer sequences for β-actin, tumor necrosis
factor (TNF)-α, interferon (INF)-β, interleukin (IL)-1β and
IL-6 are shown in Table 3. The cycle at which each sample
crossed a fluorescence threshold (Ct) was determined, and the
triplicate values for each cDNA were averaged. Analyses of
real-time PCR were done using a 2Ct relative quantification
method.
Statistical Analysis
Results are expressed as mean ± SD. Means were compared by
one-way ANOVA followed by the Fisher’s LSD test for post hoc
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TABLE 3 | Primers used for real-time PCR.
ARNm target Primers sense (S) and antisense (A)
sequences
Temp (◦C)
β-Actin S:5′- GGCTATGCTCTCCCTCACG
A:5′- CTTCTCTTTGATGTCACGCACG
60
TNF-α S:5′- TGCCTATGTCTCAGCCTCTTC
A: 5′- GAGGCCATTTGGGAACTTCT
60
INF-β S:5′- AACTTCCAAAACTGAAGACC
A:5′- AACTCTGTTTTCCTTTGACC
60
IL-6 S:5′- GACAAAGCCAGAGTCCTTCAGA
A:5′- AGGAGAGCAATTGGAAATTGGGG
60
IL-1β S:5′- TGTAATGAAAGACGGCACACC
A:5′- TCTTCTTTGGGTATTGCTTGG
60
multiple range comparisons. An alpha level of 0.05 was used.
The Statgraphics Plus 3.0 statistical package was used for the
analyses.
RESULTS
Quantification of Microglia
Iba-1 is a protein associated with major histocompatibility
complex II, which is expressed in all microglial phenotypes but
overexpressed in reactive microglia. Hence, we first used Iba-1
immunohistochemistry to evaluate the number and morphology
of microglial cells. In striatum, control animals showed a faint
Iba1 immunostaining characterized by a small number of highly-
ramified microglial cells (170.2 cell/mm2 ± 45.6; Figures 1A,B).
Treatment with LPS alone induced a transient activation of
microglia that peaked after 12 h (224.5 ± 10.3 cells/mm2;
p < 0.001; Figures 1B,C,F,I). In this brain structure, microglial
cells were bigger and exhibited thicken processes in response
to LPS treatment. The treatment with MPTP alone showed
a time-course characterized by a significant increase after
24 h (161.5 ± 19.6 and 224.2 ± 9.7 cell/mm2, respectively,
p < 0.001; Figures 1B,D,G,J). This MPTP-induced effect over
microglial cells was significantly enhanced when LPS was
administered 12 h prior to MPTP (273.8 ± 56,9 cell/mm2;
p < 0.001; Figures 1B,E,H,K). The results demonstrate
how peripheral inflammation modulates microglia brain
response during neurodegeneration. Two weeks after
treatment, number and morphology of most of microglial
cells were similar to those found in controls. Still, some
microglial cells in the striatum from LPS/MPTP- and MPTP-
treated animals showed a round, phagocytic morphology
without processes, features of chronically activated microglia
(Figure 1K).
Similar results were found when microglia were analyzed
in the SN. Strikingly, LPS treatment alone showed increased
density of microglial cells that peaked again 12 h after exposition
(156.2± 9.4; p< 0.0001; Figures 2B,C,F,I) compared to controls
(44.9± 47.2 cell/mm2, Figures 2A,B). In MPTP-treated animals,
an increase in the number of microglial cells was found at
24 h (173.5 ± 0.8 cells/mm2; p < 0.0001; Figures 2B,D,G,J).
Remarkably, LPS/MPTP-injected animals showed a stronger
microglia activation compared with animals treated with LPS
or MPTP alone, this effect being especially evident at 12 h
(337.9± 140.8 cells/mm2; p< 0.0001; Figures 2B,E,H,K). These
data demonstrate again a synergistic effect between peripheral
and central inflammation.
In the striatum, conversely, a significant number of
microglial cells was seen in the SN of MPTP-injected
animals (157 ± 25.7 cell/mm2), which further increased in
the LPS + MPTP group (220.4 ± 36.0 cells/mm2; p < 0.0001;
Figures 2B,I–K). Microglia exhibited typical morphological
features of activated cells with large bodies and thick processes
(Figure 2K). These features were even more evident than those
seen in striatal tissue (Figure 1K).
Recent transcriptomic studies have characterized the
molecular signature of microglia under different disease
conditions and identified a common disease-associated
phenotype (DAM) or microglia neurodegenerative phenotype
(Keren-Shaul et al., 2017; Krasemann et al., 2017; Mathys
et al., 2017). A selected group of genes were found to be
strongly up-regulated in the microglial phenotype associated
to neurodegeneration, including Itgax, Clec7a and Lgals3
(galectin-3), which differs from the classically M1-like pro-
inflammatory phenotype (Keren-Shaul et al., 2017; Krasemann
et al., 2017; Mathys et al., 2017). We have long characterized
novel roles associated to galectin-3 within microglial cells under
different disease conditions (Boza-Serrano et al., 2014; Burguillos
et al., 2015; Yip et al., 2017). Consequently, we analyzed
microglial galectin-3 expression under the different experimental
conditions. In agreement with previous findings, homeostatic
microglia lack galectin-3 expression (Burguillos et al., 2015).
Since most significant changes in terms of microglia density and
activation, showed by Iba1-labeled microglia, was seen at 12 h
after LPS/MPTP, we analyzed the presence of microglial galectin-
3 at this time under the different experimental conditions, in
both striatum and SN. Systemic LPS or MPTP alone failed to
induce microglial galectin-3 expression in both structures. In
contrast, in the combinative group, a strong up-regulation of
galectin-3 was found in striatum (20-fold vs. control levels;
p < 0.0001; Figure 3) and SN (6-fold vs. control levels; p < 0.01;
Figure 4).
Since most relevant microglial changes were found 12 h after
LPS/MPTP, we wanted to know if the appearance of microglia
polarization toward a neurodegenerative phenotype precedes
degenerative events in nigral dopaminergic neurons. Hence, we
performed dual confocal immunofluorescence of TH/cleaved
caspase-3 (apoptotic marker) in the ventral mesencephalon at 12
and 24 h after the different experimental conditions. No apparent
early loss of integrity of nigral dopaminergic neurons was
evident in any of the experimental conditions tested, including
LPS/MPTP at 12 h (not shown) and 24 h (Supplementary
Figure S1). Only under combined LPS/MPTP treatment was
evident the appearance of cleaved caspase-3 in the ventral
mesencephalon 24 h after. We, however, failed to detect any
TH-labeled neuron showing cleaved caspase-3 (Supplementary
Figure S1).
Overall, we conclude that systemic inflammation enhances the
switch from homeostatic to disease-associated microglia in the
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FIGURE 1 | Effect of LPS and MPTP on the activation of microglia in the striatum. Coronal sections showing Iba-1 immunoreactivity in the striatum after the different
treatments assayed. (A) Control animals. (C,F,I) Animals treated with LPS during 12 h, 24 h, and 2 weeks, respectively. (D,G,J) Animals treated with MPTP during
12 h, 24 h, and 2 weeks, respectively. (E,H,K) Animals treated with both LPS and MPTP during 12 h, 24 h, and 2 weeks, respectively. Note that LPS highly increases
the microglia activation response to MPTP injection. Scale bar: 100 µm. (B) Quantification of Iba-1-positive cells in the striatum of rats. Results are mean ± SD of at
least three independent experiments and are expressed as cell/mm2. One-way ANOVA followed by the Fischer’s LSD post hoc test for multiple comparisons was
used for statistical analysis, with α = 0.05: a, compared with the control; b, compared with the LPS group; c, compared with the MPTP group; p < 0.001.
nigrostriatal system in response to MPTP treatment preceding
the onset of nigrostriatal dopaminergic degeneration.
Quantification of the Levels of TNF-α,
IFN-β, IL-1β, and IL-6 mRNAs
We quantified the expression of mRNAs encoding for classical
neurotoxic pro-inflammatory markers including TNF-α, IFN-β,
IL-1β, and IL-6 in striatum and SN of mice sacrificed 12 h after
the different experimental conditions including: control animals,
LPS-, MPTP-, and LPS/MPTP-injected animals. Systemic LPS
induced a clear pro-inflammatory response in the nigrostriatal
system with significant increase in mRNA levels for TNF-
α and IL-6 in striatum and IFN-β and IL-6 in the ventral
mesencephalon (Figure 5). In contrast, the effect of MPTP alone
was negligible. Yet, significant increase of TNF-α expression was
found in striatum (Figure 5A) and also IFN- β in SN (Figure 5F).
Highest pro-inflammatory response was clearly achieved when
LPS and MPTP were combined, with significant increase of
TNF-α, IFN-β, and IL-6 in striatum and SN (Figure 5). Statistical
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FIGURE 2 | Effect of LPS and MPTP on the activation of microglia in the SN. Coronal sections showing Iba-1 immunoreactivity in the SN. (A) Control animals. (C,F,I)
Animals treated with LPS during 12 h, 24 h, and 2 weeks, respectively. Note that LPS increase microglial activation, especially after 12 h. (D,G,J) Animals treated
with MPTP during 12 h, 24 h, and 2 weeks, respectively. (E,H,K) Animals treated with both LPS and MPTP during 12 h, 24 h, and 2 weeks, respectively. Note that
LPS highly increases the microglia activation response to MPTP injection. Scale bar: 50 µm. (B) Quantification of Iba-1-positive cells in the SN of rats. Results are
mean ± SD of at least three independent experiments and are expressed as cell/mm2. One-way ANOVA followed by the Fischer’s LSD post hoc test for multiple
comparisons was used for statistical analysis, with α = 0.05: a, compared with the control; b, compared with the LPS group; c, compared with the MPTP group;
p < 0.001.
analysis demonstrated that combined LPS/MPTP treatment acted
synergistically to increase mRNA levels for TNF-α and IFN-β in
both striatum and SN (Figure 5).
Blood–Brain Barrier Impairment
We first analyzed the expression pattern of occludin (an integral
membrane protein that directly regulates the tight junction
paracellular permeability) 12 h after challenge (maximal response
of microglia density and activation) (Kuan et al., 2016). We
analyzed both, striatum and SN and found a decrease in the
expression of this protein in animals treated concomitantly
with LPS and MPTP (Supplementary Figure S2). This finding
suggests an alteration in the BBB permeability in the nigrostriatal
system. Consequently, we next quantitatively analyzed the
integrity of the BBB. To achieve this, we studied IgG extravasation
into the nigrostriatal system 12 h after challenge. Treatment
with LPS or MPTP alone failed to alter BBB integrity in terms
of IgG extravasation (Figures 6A–C,E). However, combined
LPS/MPTP treatment highly altered BBB integrity in the striatum
as demonstrated by IgG extravasation (Figures 6D,E). Similar
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FIGURE 3 | Lipopolysaccharide (LPS)/MPTP induce the appearance of
galectin-3 (Gal3)-expressing microglial cells in striatum. Immunofluorescence
for Iba1 (A,D,G,J,M) and Gal3 (B,E,H,K,N) in the different treatment assayed.
Only LPS/MPTP group shows a robust expression of Gal3 microglial cells
(merged images, C,F,I,L,O). Scale bar: 100 µm. (M–O) Shows high
magnification pictures of Iba-1, Gal3 and merge image of the LPS/MPTP
group. Scale bar: 500 µm. (P) Quantification of Iba-1/Gal3 co-localizing cells
in the different treatment assayed. Results are mean ± SD of at least three
independent experiments and are expressed as number of cells. One-way
ANOVA followed by the Fischer’s LSD post hoc test for multiple comparisons
was used for statistical analysis, with α = 0.05: ∗, compared with the control;
p < 0.0001.
results were found in SN, where only LPS/MPTP group
showed increased immunoreactivity of IgG into the analyzed
brain parenchyma (Figures 6F–J). We additionally extended
our analysis to other brain areas not directly related to the
FIGURE 4 | Lipopolysaccharide/MPTP induce the appearance of galectin-3
(Gal3)-expressing microglial cells in SN. Immunofluorescence for Iba1
(A,D,G,J,M) and Gal3 (B,E,H,K,N) in the different treatment assayed. Only
LPS/MPTP group shows a clear expression of Gal3 microglial cells (merged
images, C,F,I,L,O). Scale bar: 100 µm. (M–O) Shows high magnification
pictures of Iba-1, Gal3 and merge image of the LPS/MPTP group. Scale bar:
500 µm. (P) Quantification of Iba-1/Gal3 co-localizing cells in the different
treatment assayed. Results are mean ± SD of at least three independent
experiments and are expressed as number of cells. One-way ANOVA followed
by the Fischer’s LSD post hoc test for multiple comparisons was used for
statistical analysis, with α = 0.05: ∗, compared with the control; p < 0.05.
nigrostriatal system. Thus, we analyzed BBB integrity in cerebral
cortex and midbrain (adjacent to the superior colliculus) in
response to LPS, MPTP, and LPS + MPTP 12 h after challenge.
Interestingly, BBB disruption was again observed in response
to LPS + MPTP but not to LPS or MPTP alone in both
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FIGURE 5 | Effect of LPS and MPTP on the expression of TNF-α, IFN-β, IL-1β, and IL-6 mRNAs in the striatum and SN. Quantification of mRNAs expression was
made by real-time RT-PCR. Results are mean ± SD of at least three independent experiments, and are expressed as percentage of controls. Statistical signification:
One-way ANOVA followed by the LSD post hoc test for multiple range comparisons; a, compared with control; b, compared LPS; c, compared with MPTP.
(A) TNF-α mRNA in striatum, p < 0.001; (B) INF-β mRNA in striatum, p < 0.001; (C) IL-6 mRNA in striatum, p < 0.01; (D) IL-1β mRNA in striatum; (E) TNF-α mRNA
in SN, p < 0.001; (F) INF-β mRNA in SN, p < 0.001; (G) IL-6 mRNA in SN, p < 0.001; (H) IL-1β mRNA in SN.
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FIGURE 6 | Effect of LPS and MPTP on the BBB integrity in the striatum and SN. Normal pattern of IgG immunoreactivity in control animals in striatum (A) and SN
(F). Note the absence of IgG immunoreactivity. LPS and MPTP alone failed to induce a significant IgG extravasation in striatum (B,C) and SN (G,H). IgG
extravasation is, however, strongly induced 12 h after the combination of LPS and MPTP. Note the atypical presence of IgG immunostaining in striatum (D) and SN
(I). Scale bar: 100 µm. Quantification of the area expressing IgG immunoreactivity in striatum (E) and SN (J). Results are mean ± SD of at least three independent
experiments and are expressed as % of total area. One-way ANOVA followed by the Fischer’s LSD post hoc test for multiple comparisons was used for statistical
analysis. ∗, different of the rest of the treatment assayed; p < 0.05.
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 November 2018 | Volume 12 | Article 398
fncel-12-00398 November 5, 2018 Time: 7:44 # 11
García-Domínguez et al. Systemic LPS Increases MPTP-Induced Death
FIGURE 7 | Effect of LPS and MPTP on the A1 astrocytic phenotype in the
striatum. Immunofluorescent double labeling of GFAP and C3 shows the
absent of C3 immunostaining in non-reactive astrocytes present in the control
striatum (A–C). A similar pattern was seen in the striatum of animals treated
with LPS (D–F) or MPTP (G–I) alone. However, the combination of LPS and
MPTP clearly induced the expression of A1 astrocytic phenotype in striatum
(J–L). Scale bar: 100 µm.
analyzed areas (Supplementary Figure S3), further supporting
that peripheral systemic inflammation and MPTP synergistically
enhance/induce BBB breakdown.
Induction of A1 Astrocytic Phenotype
Reactive astrocytes showing the A1 phenotype have been recently
identified and found to be neurotoxic as opposed to A2 astrocytes,
which are neuroprotective (Liddelow et al., 2017). Reactive
microglia induces reactive A1 astrocyte polarization, which
highly up-regulates complement component 3 (C3) expression,
in sharp contrast to A2 astrocytes (Liddelow et al., 2017).
Therefore, we have performed a double immunofluorescence
confocal analysis in order to study the astrocytic phenotype
in our experimental conditions. In control animals, astrocytes
were not activated and failed to express C3, both in striatum
and SN (Figures 7, 8A–C). Treatment with LPS or MPTP
alone also failed to induce the A1 phenotype in striatum, at
least at the post-injection time analyzed (12 h) (Figures 7D–I).
However, the combination of both treatments clearly induced
the A1 neurotoxic phenotype in the striatum (Figures 7J–
L). In the SN, LPS alone again failed to induce the A1
FIGURE 8 | Effect of LPS and MPTP on the A1 astrocytic phenotype in the
SN. Immunofluorescent double labeling of GFAP and C3 shows the absent of
C3 immunostaining in non-reactive astrocytes present in the control SN
(A–C). A similar pattern was seen in the SN of animals treated with LPS (D–F)
alone. Some neurotoxic astrocytes showing the A1 phenotype are present in
the SN of animals treated with MPTP alone (G–I). Again, the combination of
LPS and MPTP clearly induced the expression of A1 astrocytic phenotype in
SN (J–L). Scale bar: 100 µm.
astrocytic phenotype at 12 h post-injection (Figures 8D–F).
However, A1 reactive astrocytes population were minority
after the treatment with MPTP alone (Figures 8G–I). In
contrast, this phenotype shift was much more evident when LPS
and MPTP were combined (Figures 8J–L). Collectively, these
data demonstrate that peripheral inflammation early triggers
A1 astrocytic phenotype under conditions of dopaminergic
neurodegeneration.
Dopaminergic Neuronal Loss
We used TH antibody to label dopaminergic neurons in SN
of mice treated with LPS, MPTP, combined LPS/MPTP and
controls. Analysis performed 2 weeks after the neurotoxin
administration showed clear neurodegenerative features. This
result was further evaluated by stereology. An even distribution
of TH-positive neurons was seen in the SN of control animals
(5803 ± 604; Figures 9A,E), showing that the primary antibody
was highly selective to dopaminergic neurons. Our stereological
analysis of dopaminergic neurons in the SN agrees with
previously published reports (Smeyne et al., 2016; Alam et al.,
2017; Ip et al., 2017). As expected, MPTP-treated mice showed
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FIGURE 9 | Effect of LPS and MPTP on the dopaminergic neurons.
(A) Coronal section showing TH immunoreactivity in a control animal. (B) TH
immunoreactivity 2 weeks after the injection of LPS. No significant changes
are observed. (C) TH immunoreactivity 2 weeks after the injection of MPTP.
There is a clear loss of dopaminergic neurons in the SN. (D) TH
immunoreactivity 2 weeks after the injection of both LPS and MPTP. The loss
of neurons is higher. Scale bar: 500 µm. (E) Quantification of the number of
TH-positive cells. Results are mean ± SD of three independent experiments,
and are expressed as TH-positive cells within the bounded area of the SN.
Statistical signification (ANOVA followed by the LSD post hoc test for multiple
comparisons): a, compared with control; b, compared with MPTP; p < 0.001.
a significant decrease of 60.7% in the number of dopaminergic
neurons of SN (Figures 9C,E, p < 0.001). LPS-injected animals
failed to induce loss of nigral dopaminergic neurons 2 weeks
after the treatment (4770 ± 1924; Figures 9B,E). Strikingly, LPS
and MPTP acted synergistically and dopaminergic cell death
was significantly increased compared with MPTP alone, reaching
83.6% of cell loss (Figures 9D,E, p< 0.001).
We also analyzed dopaminergic terminals in the striatum
2 weeks after neurotoxin administration by using TH-
immunohistochemistry and neurochemical analysis of DA
and its metabolites. LPS alone failed to alter DA levels in
the striatum as compared with control non-lesioned animals
(Figures 10A,B,E). MPTP treatment largely decreased DA
levels (about 40% control levels; Figures 10C,E). Combined
LPS/MPTP further decreased DA levels (about 25% control
levels; Figures 10D,E), but failed to reach statistical significance,
thus suggesting compensatory mechanisms at the dopaminergic
terminal.
DISCUSSION
In this study we demonstrate that peripheral inflammation
induced by a single i.p. injection of LPS sensitizes microglia in
the nigrostriatal system in response to MPTP, a well-established
model of PD in terms of strong up-regulation of galectin-3,
a recently identified microglial disease-associated phenotypic
marker (Keren-Shaul et al., 2017; Krasemann et al., 2017; Mathys
et al., 2017), and classical pro-inflammatory neurotoxic factors.
These microglial changes were accompanied by induction of
A1 reactive neurotoxic astrocytes in the nigrostriatal system,
and, importantly, preceding dopaminergic neurodegenerative
events. Notably, peripheral inflammation and MPTP acted
synergistically to induce BBB breakdown and enhanced loss of
the nigrostriatal dopaminergic system.
Increasing evidence supports a deleterious role of peripheral
inflammation in different neurodegenerative diseases (Herrera
et al., 2015). In order to demonstrate our hypothesis,
microglial activation was first analyzed in terms of density
and morphological features in striatum and SN at 12 h, 24 h,
and 2 weeks after LPS/MPTP treatment. Our results show that
LPS-induced peripheral inflammation increases the number
of microglial cells in both SN and striatum after the treatment
with MPTP in a time-dependent manner, peaking at 12 h after
treatment. Moreover, at this time point most cells showed a
typical morphology of activated microglia. However, Iba1-
labeled microglia fail to provide clues about the phenotypic
nature of one or even different subsets of polarized microglia.
Recent transcriptomic studies have characterized the molecular
signature of microglia to uncover different microglial activation
states associated to aging (Holtman et al., 2015; Galatro et al.,
2017) and disease (Keren-Shaul et al., 2017; Krasemann et al.,
2017; Mathys et al., 2017). Transcriptional profiles of isolated
microglia from different mouse models of aging and different
neurodegenerative diseases have been analyzed and found
a strikingly similar transcriptional network in all of them
(Holtman et al., 2015). All these conditions showed strong
up-regulation of Lgals3 (galectin-3) and very interestingly, it
was identified as a major instrumental hub gene in driving the
previously referred activated microglia phenotype (Holtman
et al., 2015). Recent transcriptomic studies at the single cell level
have indeed identified a common microglia disease-associated
phenotype (Keren-Shaul et al., 2017; Krasemann et al., 2017;
Mathys et al., 2017). A remarkable feature in this microglial
phenotype is a strong up-regulation of galectin-3 (Keren-Shaul
et al., 2017; Krasemann et al., 2017; Mathys et al., 2017).
Taken together, galectin-3 emerges as a good marker to label
the disease-associated microglia phenotype. Systemic LPS has
been shown to induce a classical M1-like pro-inflammatory
activation state different to that seen under disease conditions
(Keren-Shaul et al., 2017; Krasemann et al., 2017; Mathys et al.,
2017). Supporting this, we failed to detect galectin-3 expression
in microglial cells in response to systemic LPS injection, even
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FIGURE 10 | Effect of LPS and MPTP on the dopaminergic terminals. (A) Coronal section showing TH immunoreactivity in a control animal. (B) TH immunoreactivity
2 weeks after the injection of LPS. No significant changes are observed. (C) TH immunoreactivity 2 weeks after the injection of MPTP. There is a clear loss of TH
immunoreactivity in the striatum. (D) TH immunoreactivity 2 weeks after the injection of both LPS and MPTP. Loss of TH immunoreactivity is higher. Scale bar:
500 µm. (E) Amounts of dopamine in the striatum of control and treated animals. Numbers are mean ± SD of at least three independent experiments and are
expressed as nanograms per gram of wet tissue.
though microglia exhibited typical morphological features of
activation. The same was true after MPTP challenge, at least at the
post-injection time examined (12 h). Remarkably, combination
of systemic LPS and MPTP robustly up-regulated galectin-3
mRNA-expressing microglial cells in the nigrostriatal system, an
indication of a switch from homeostatic to disease-associated
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phenotype preceding the appearance of neurodegenerative
events in nigral dopaminergic neurons.
At present, it is evident the potential ability of microglia
to show a graded phenotypic polarization or even different
polarization states. Consequently, we also analyzed different pro-
inflammatory mediators, including TNF-α, which is considered
one of the most significant deleterious players in the context of
dopaminergic degeneration (Blaylock, 2017). As expected, our
results demonstrate that LPS alone is able to induce an increase
in the expression levels of several pro-inflammatory cytokines
in both the striatum and SN, thus supporting the existence of a
microglia pro-inflammatory phenotype in response to systemic
LPS injection. From the different experimental conditions
tested, it was evident that combined systemic LPS and MPTP
treatment led to a more intense pro-inflammatory response in the
nigrostriatal system. Especially relevant was the dramatic increase
of TNF-α mRNA expression in the ventral mesencephalon (25-
fold higher than that seen after either LPS or MPTP treatment).
A synergistic effect of peripheral inflammation and MPTP in
up-regulating TNF-α was also observed in the striatum, the
two key brain areas in dopaminergic neurodegeneration. The
inflammatory cytokines TNF-α and IL-1α are major components
of the neuroinflammatory response in PD pathogenesis (Sriram
et al., 2006; Godoy et al., 2008; McCoy and Tansey, 2008; De
Lella Ezcurra et al., 2010; Harms et al., 2012). Interestingly,
TNF-α has also been shown to play a critical role in inducing
BBB leakage following MPTP administration in terms of
extravasation of FITC-labeled albumin (Zhao et al., 2007). BBB
integrity is critical in preventing brain entrance of environmental
factors, neurotoxic blood-derived products and peripheral cells
and associated inflammatory response and neurodegenerative
conditions (Sweeney et al., 2018). Moreover, there is evidence
supporting a dysfunctional BBB in PD (Kortekaas et al., 2005).
Consequently, we analyzed BBB integrity. It is important to
state that serum protein leakage in response to MPTP has
been analyzed in mice (Brochard et al., 2009) and found a
transient BBB disruption (detectable at 6 h but not at 12 h after
MPTP treatment). We analyzed BBB disruption in terms of IgG
extravasation at 12 h, and hence comparable to that seen by
Brochard et al. (2009). In keeping with this study, we found
absence of BBB leakage in striatum and SN at 12 h when MPTP
was administered alone. LPS-induced systemic inflammation
also failed to alter BBB integrity in terms of IgG extravasation.
Interestingly, combined LPS/MPTP triggered a quite robust BBB
disruption, thus highlighting the critical deleterious effect of
systemic inflammation under conditions of brain injury. It could
be argued that local effect of LPS in the peritoneal cavity could
increase absorption of MPTP and hence underlying some of the
differences seen between MPTP and LPS + MPTP groups. This
is, however, unlikely illustrated by the lack of a graded response
in terms of BBB disruption when comparing MPTP group (no
effect at 12 h) with LPS + MPTP group (robust effect at 12 h).
Altogether, our study supports the view that systemic LPS and
MPTP act synergistically.
Recent evidence has shown that astroglia also seem to play
an important deleterious role in neurodegenerative diseases.
Hence, two different types of reactive astrocytes, termed A1
and A2 in analogy to the M1/M2 macrophage nomenclature,
have been recently described (Zamanian et al., 2012; Liddelow
et al., 2017). While A1 astrocytes up-regulate genes previously
shown to be harmful, A2 astrocytes are protective through the
up-regulation of many neurotrophic factors. Pro-inflammatory
microglia are the cell responsible for driving astrocytes from a
resting state to the A1 phenotype (Liddelow et al., 2017). Once
we have demonstrated that peripheral inflammation sensitizes
microglia to acquire both, a disease-associated and a pro-
inflammatory phenotype in response to MPTP, we wondered if
this effect was accompanied by induction of astrogliosis with the
neurotoxic A1 astrocytic phenotype, which express high levels
of the C3 component of the complement cascade (Liddelow
et al., 2017). Our immunofluorescence study clearly revealed that
treatment with both, LPS and MPTP, is a very potent inducer
of A1 neurotoxic astrocytes in the nigrostriatal dopaminergic
system. This finding highlights the critical importance of
peripheral inflammation in driving both, microglia and astroglia,
into potentially neurotoxic phenotypes in vivo. Consequently,
we next wanted to know if this neuroinflammatory scenario
could increase dopaminergic neuronal death in the ventral
mesencephalon following MPTP injection. Our results showed
that systemic LPS exacerbates damage to the dopaminergic
system in the ventral mesencephalon in response to MPTP, thus
confirming the prominent role of peripheral inflammation in
regulating brain neurotoxic glia response to subsequent damage
to the nigrostriatal dopaminergic system.
Our study revitalizes the importance of peripheral
inflammation in the context of neurodegeneration, and
particularly PD (Herrera et al., 2015). We provide evidence
that conditions associated to a peripheral inflammatory process
may constitute a risk factor for PD. In addition, considering
that the BBB is a potential gateway to the environment, we
demonstrate that peripheral inflammation ease this interaction.
It should be noted that exposure to environmental neurotoxins
is assumed to be a significant contributor to nerve cell loss
(neurodegeneration) in certain locations in the midbrain of PD
patients. Consequently, our findings may be important in the
context of PD etiology as environmental exposure is considered
an accepted risk factor for PD, from which, pesticide exposure
showed the strongest association (Kalia and Lang, 2015).
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FIGURE S1 | Early Analysis (24 h) of integrity of nigral dopaminergic neurons and
appearance of cleaved caspase-3 in the ventral mesencephalon after LPS/MPTP
treatment. Immunofluorescence of TH (A,D,G,J), and cleaved caspase-3
(B,E,H,K). Merge images (C,F,I,L). Note the appearance of cleaved caspase-3 in
response to combined LPS/MPTP treatment; also note that dopaminergic
neurons failed to co-localize with cleaved caspase-3. Scale bar: 200 µm.
FIGURE S2 | Occludin immunostaining in a control animal. Normal pattern of
occludin is seen in striatum (A) and SN (C). Occludin immunostaining in a
LPS/MPTP treated animal. 12 h after the injection of both LPS and MPTP. Images
show a clear decrease in the immunoreactivity of occludin in the striatum (B) and
SN (D), especially in the areas surrounding the vessels.
FIGURE S3 | Normal pattern of IgG immunoreactivity in control animals in Cortex
(A) and Midbrain (adjacent to superior colliculus) (B). Note the absence of IgG
immunoreactivity. IgG extravasation is induced 12 h after the combination of LPS
and MPTP. Note the atypical presence of IgG immunostaining in cortex (C) and
midbrain (D). Scale bar: 100 µm.
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